Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/31612
Type
ArticleCopyright
Open access
Sustainable Development Goals
10 Redução das desigualdadesCollections
- IOC - Artigos de Periódicos [12978]
Metadata
Show full item record
TIME TO HARMONIZE DENGUE NOMENCLATURE AND CLASSIFICATION
Author
Affilliation
Rega Institute for Medical Research, Clinical and Epidemiological Virology. Department of Microbiology and Immunology. Leuven, Belgium / University of Oxford. Nuffield Department of Mediciine. Oxford, UK.
Rega Institute for Medical Research, Clinical and Epidemiological Virology. Department of Microbiology and Immunology. Leuven, Belgium / Vrije Universiteit Brussel. Department of Computer Science. Artifical Intelligence Lab. Brussels, Belgium.
University of Oxford. Nuffield Department of Mediciine. Oxford, UK.
Vrije Universiteit Brussel. Department of Computer Science. Artifical Intelligence Lab. Brussels, Belgium.
Centers for Disease Control and Prevention. Dengue Branch. Division of Vector-Borne Diseases. San Juan, Porto Rico.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Flavivírus. Rio de Janeiro, RJ, Brasil.
Rega Institute for Medical Research, Clinical and Epidemiological Virology. Department of Microbiology and Immunology. Leuven, Belgium / Universidade Nova de Lisboa. Instituto de Higiene e Medicina Tropical. Unidade de Microbiologia. Global Health and Tropical Medicine. Lisboa, Portugal.
Centers for Disease Control and Prevention. Dengue Branch. Division of Vector-Borne Diseases. San Juan, Porto Rico.
Rega Institute for Medical Research, Clinical and Epidemiological Virology. Department of Microbiology and Immunology. Leuven, Belgium.
Rega Institute for Medical Research, Clinical and Epidemiological Virology. Department of Microbiology and Immunology. Leuven, Belgium / Vrije Universiteit Brussel. Department of Computer Science. Artifical Intelligence Lab. Brussels, Belgium.
University of Oxford. Nuffield Department of Mediciine. Oxford, UK.
Vrije Universiteit Brussel. Department of Computer Science. Artifical Intelligence Lab. Brussels, Belgium.
Centers for Disease Control and Prevention. Dengue Branch. Division of Vector-Borne Diseases. San Juan, Porto Rico.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Flavivírus. Rio de Janeiro, RJ, Brasil.
Rega Institute for Medical Research, Clinical and Epidemiological Virology. Department of Microbiology and Immunology. Leuven, Belgium / Universidade Nova de Lisboa. Instituto de Higiene e Medicina Tropical. Unidade de Microbiologia. Global Health and Tropical Medicine. Lisboa, Portugal.
Centers for Disease Control and Prevention. Dengue Branch. Division of Vector-Borne Diseases. San Juan, Porto Rico.
Rega Institute for Medical Research, Clinical and Epidemiological Virology. Department of Microbiology and Immunology. Leuven, Belgium.
Abstract
Dengue virus (DENV) is estimated to cause 390 million infections per year worldwide. A quarter of these infections manifest clinically and are associated with a morbidity and mortality that put a significant burden on the affected regions. Reports of increased frequency, intensity, and extended geographical range of outbreaks highlight the virus's ongoing global spread. Persistent transmission in endemic areas and the emergence in territories formerly devoid of transmission have shaped DENV's current genetic diversity and divergence. This genetic layout is hierarchically organized in serotypes, genotypes, and sub-genotypic clades. While serotypes are well defined, the genotype nomenclature and classification system lack consistency, which complicates a broader analysis of their clinical and epidemiological characteristics. We identify five key challenges: (1) Currently, there is no formal definition of a DENV genotype; (2) Two different nomenclature systems are used in parallel, which causes significant confusion; (3) A standardized classification procedure is lacking so far; (4) No formal definition of sub-genotypic clades is in place; (5) There is no consensus on how to report antigenic diversity. Therefore, we believe that the time is right to re-evaluate DENV genetic diversity in an essential effort to provide harmonization across DENV studies.
Share